An expert consensus has been released by the Joint European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) reviewing the pathophysiological context and indications for pVADs in different clinical settings. It also provides guidance regarding the clinical management of patients requiring pVADs. A quick overview is made on the state-of-the art of short-term mechanical circulatory support according to different indications. Additional discussions on the handling of complications, anticoagulation and weaning are also provided. The appendix section describes the theoretical basis for the use of different MCS devices, including how their effects differ. The review has been published on EuroIntervention. Please follow this link for the full publication.
Dr. Ota Hlinomaz, interventional cardiologist at CINRE hospital in Slovak Republic presented during the EuroPCR 2021: Improving outcomes of high-risk protected distal left main intervention by pulsatile circulatory support system. For more information please follow this link.
B.G. Alekyan, N.G. Karapetyan, A.Ya. Novak , G.P. Plotnikov, Yu.B. Knysh, G.S. Grigoryan A.V. Vishnevsky National Medical Research Center of Surgery, Moscow Please follow this link: Casereport Moscow September 2020 for the full casereport
Carsten Tschöpe, Alessio Alogna, Alessandro Faragli, Karin Klingel, Gunther Schmidt, Torsten Wolfgang Heilmann, Marcelo B. Bastos and Frank Spillmann Please follow this link: Casereport Berlin September 2020 for the full casereport
S. Tzikas*, C.H. Papadopoulos, A.P. Evangeliou, V. Vassilikos 3rd Department of Cardiology, Ippokrateio General Hospital, Aristotle University of Thessaloniki, Greece Please follow this link: Casereport Greece May 2020 for the full casereport.
Prof.Dr. Nicolas van Mieghem, Erasmus Medical Center Brief Summary: The objective of this study is to determine ventricular loading conditions during and after PulseCath® iVAC 2L support, and assess its impact on specific load dependent humoral factors and cardiac enzymes. These specific patterns are so far unknown and will be compared with the validated FDA-cleared and CE marked Impella CP. Three cases with Impella CP will be performed in this study to obtain the exact same measurements for comparing purposes. For more information about this trial, please follow this link.
Marcelo B Bastos , Maarten P van Wiechen & Nicolas M Van Mieghem*, Department of Interventional Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands *Author for correspondence: Tel.: +31 010 703 5260; Fax: +31 010 436 9154; firstname.lastname@example.org Please follow this link for the publication.
B. Bastos M. 1 , JJ. Schreuder 1 , J. Daemen 1 , CA. Den Uil 1,2 , NM. Van Mieghem 1 (1) Erasmus Medical Center, Interventional Cardiology, Rotterdam, Netherlands (2) Erasmus Medical Center, Department of Intensive Care Medicine, Rotterdam, Netherlands Click here to read the Poster ACURE 20.08.219
Alexander Samol,1 Blerim Luani,2 Sven Kaese,3 Marcus Wiemer3 1Johannes Wesling University Hospital, Department of Cardiology and Critical Care Medicine, Minden, Germany; 2 Ruhr University Bochum, Minden, Germany; 3 Johannes Wesling University Hospital Minden, Minden, Germany Read here the full Jacc Publication B319.full Jacc Publication Ivac vs Impella
Marcelo Barros Bastos, MD; Joost Daemen, MD, PhD; Nicolas M. Van Mieghem*, MD, PhD Department of Cardiology, Erasmus Medical Center, Thoraxcentrum, Rotterdam, the Netherlands Click here for publication: 2018 Haemodynamic impact of a new pulsatile circulatory support in high risk coronary stenting